Uvantis Therapeutics, Inc.
About Uvantis Therapeutics, Inc.
Uvantis Therapeutics is a biotechnology company developing live biotherapeutic products targeting the urinary microbiome to prevent and treat recurrent urinary tract infections (rUTIs). The company focuses on antibiotic-sparing solutions for urinary health and balance by advancing microbiome-driven approaches to urologic disease. Its lead program centers on a defined microbial therapeutic designed to colonize the urinary tract and reduce pathogen overgrowth. Uvantis aims to deliver durable, non-antibiotic treatment options that address a major unmet clinical need while helping reduce antibiotic resistance.
- 🔗 Uvantis Therapeutics - Antibiotic-sparing solutions for urinary health and balance.
- 🔗 New venture showcase- Company Bio (2 pm -3:15 pm) | Office of Technology Commercialization | Georgetown University
- 🔗 Uvantis Therapeutics
- 🔗 Biotech Funding 2025 Tracker: Follow the Latest Raises ...
- 🔗 Top 20 biotech startups raise $2.9B in Q1 2024 funding surge
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Developing live biotherapeutics to target the urinary microbiome for rUTI prevention and treatment.
- Focuses on antibiotic-sparing solutions to address recurrent urinary tract infections and reduce resistance.
- Early-stage company founded in 2025 with headquarters in Bethesda, Maryland.
- Specializes in bladder health and urobiome modulation through defined microbial therapeutics.
Ask StreetZero about Uvantis Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account